fda warning letters compounded semaglutide tirzepatide 2025 Beyond the Headlines: to GLP-1 Compounders FDA issued 25 warning letters

13 Past studies have shown that GLP-1 receptor activation reduces fMRI brain response to visual food cues in the insula, amygdala, orbitofrontal cortex, and putamen

Consequently, ET seems to prevent intracellular signaling (147)

Inspired by holiday treats, these ultra-soothing balms wrap your lips in buttery softness and dessert-level deliciousness

SELECT Trial The SELECT trial, one of the largest cardiovascular outcomes trials in obesity medicine, enrolled over 17,000 participants with established cardiovascular disease and obesity or overweight (without diabetes) and demonstrated a 20% reduction in MACE with semaglutide 2.4 mg